Compare SoFi Technologies Inc (SOFI) vs 10X Genomics Inc (TXG) Price & Performance

SoFi Technologies (SOFI) trades at $17.64, up 2.08% today, amid a bearish technical signal but strong recent earnings beats. The stock is near its consensus price target low of $17.00, with revenue growth accelerating to $3.61 billion in 2025 and a net income margin of 13.32%. Cash flow trends show heavy reliance on financing activities, while assets have grown to $36.25 billion as of 2024. Recent news highlights upcoming Q2 2026 earnings on July 29, with management guiding for 30% top-line growth.

The outlook for SOFI hinges on sustained revenue expansion and profitability improvements, but risks include negative operating cash flows and competitive pressures. Analyst sentiment is mixed with a 33.33% buy rating, suggesting cautious optimism if execution meets guidance. The stock presents a potential opportunity if Q2 earnings beat expectations, yet volatility remains high given its fintech exposure and macroeconomic sensitivity.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.